Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade

Cullinan Therapeutics, Inc. (NASDAQ:CGEM)’s stock price gapped up prior to trading on Thursday after Wedbush raised their price target on the stock from $39.00 to $42.00. The stock had previously closed at $19.60, but opened at $20.72. Wedbush currently has an outperform rating on the stock. Cullinan Therapeutics shares last traded at $20.4230, with a volume of 243,271 shares changing hands.

Several other research analysts have also recently weighed in on CGEM. Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. BTIG Research lifted their target price on shares of Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Cullinan Therapeutics in a research note on Monday, June 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cullinan Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.86.

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the sale, the insider owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. This represents a 4.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.60% of the company’s stock.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analysts maintain a favorable view of Cullinan Therapeutics. The company received an average “Moderate Buy” rating, while HC Wainwright reiterated its “Buy” rating and $30 price target—well above the roughly $19.60 reference price. Cullinan Therapeutics Receives Average Rating of Moderate Buy from Analysts
• Positive Sentiment: HC Wainwright’s 2027 quarterly forecasts call for progressively smaller losses, including estimated EPS of $(0.77) in the first quarter and $(0.82) in the fourth quarter, suggesting expectations for gradual improvement over time. Cullinan Therapeutics analyst estimates
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior report. With a zero days-to-cover ratio, the data provides no evidence of meaningful short-selling pressure or a potential short squeeze.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a $(3.53) loss from $(3.42), and cut its third-quarter 2026 estimate to $(0.90) from $(0.87) and fourth-quarter estimate to $(0.93) from $(0.90). The revisions reinforce that Cullinan remains loss-making and may require continued spending or financing while advancing its pipeline.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its stake in shares of Cullinan Therapeutics by 62.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after acquiring an additional 1,036 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in Cullinan Therapeutics during the 4th quarter worth approximately $31,000. CWM LLC increased its stake in Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock worth $40,000 after purchasing an additional 1,318 shares during the period. Allworth Financial LP purchased a new position in Cullinan Therapeutics in the 2nd quarter worth approximately $53,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Cullinan Therapeutics during the second quarter valued at approximately $53,000. 86.31% of the stock is owned by institutional investors.

Cullinan Therapeutics Stock Up 2.2%

The stock has a market cap of $1.29 billion, a P/E ratio of -6.51 and a beta of 0.01. The firm’s fifty day moving average price is $16.81 and its 200-day moving average price is $14.99.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). Sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.